ATE540673T1 - Verwendung von a3-adenosin-rezeptor-agonisten bei der behandlung von osteoarthritis - Google Patents

Verwendung von a3-adenosin-rezeptor-agonisten bei der behandlung von osteoarthritis

Info

Publication number
ATE540673T1
ATE540673T1 AT06821594T AT06821594T ATE540673T1 AT E540673 T1 ATE540673 T1 AT E540673T1 AT 06821594 T AT06821594 T AT 06821594T AT 06821594 T AT06821594 T AT 06821594T AT E540673 T1 ATE540673 T1 AT E540673T1
Authority
AT
Austria
Prior art keywords
treatment
osteoarthritis
a3ar
agonist
adenosine receptor
Prior art date
Application number
AT06821594T
Other languages
English (en)
Inventor
Pnina Fishman
Original Assignee
Can Fite Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Can Fite Biopharma Ltd filed Critical Can Fite Biopharma Ltd
Application granted granted Critical
Publication of ATE540673T1 publication Critical patent/ATE540673T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
AT06821594T 2005-11-30 2006-11-29 Verwendung von a3-adenosin-rezeptor-agonisten bei der behandlung von osteoarthritis ATE540673T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74063105P 2005-11-30 2005-11-30
PCT/IL2006/001374 WO2007063538A1 (en) 2005-11-30 2006-11-29 Use of a3 adenosine receptor agonist in osteoarthritis treatment

Publications (1)

Publication Number Publication Date
ATE540673T1 true ATE540673T1 (de) 2012-01-15

Family

ID=37872156

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06821594T ATE540673T1 (de) 2005-11-30 2006-11-29 Verwendung von a3-adenosin-rezeptor-agonisten bei der behandlung von osteoarthritis

Country Status (12)

Country Link
US (2) US20080300213A1 (de)
EP (1) EP1959939B1 (de)
JP (2) JP5339916B2 (de)
KR (1) KR101101252B1 (de)
CN (1) CN101330909B (de)
AT (1) ATE540673T1 (de)
AU (1) AU2006321165B2 (de)
BR (1) BRPI0619395A2 (de)
CA (1) CA2622879C (de)
DK (1) DK1959939T3 (de)
ES (1) ES2379591T3 (de)
WO (1) WO2007063538A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200500281A (es) * 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0500785D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
GB0607950D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
PT2013211E (pt) 2006-04-21 2012-06-21 Novartis Ag Derivados de purina para utilização como agonistas de receptores a2a de adenosina
GB0607953D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607944D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
EP1889846A1 (de) 2006-07-13 2008-02-20 Novartis AG Purinderivate als A2a Agonisten
EP1903044A1 (de) * 2006-09-14 2008-03-26 Novartis AG Adenosinderivate als Agonisten des A2A-Rezeptors
JP2010508835A (ja) * 2006-11-10 2010-03-25 ノバルティス アーゲー シクロペンテンジオールモノアセテート誘導体
HUE034474T2 (en) 2007-03-14 2018-02-28 Can Fite Biopharma Ltd Method for the synthesis of IB-meca
IL184620A0 (en) * 2007-07-15 2008-01-20 Can Fite Biopharma Ltd Composition for the treatment of inflammation
ES2531828T3 (es) 2008-03-31 2015-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Derivados de purina como agonistas selectivos de los receptores A3 de adenosina
US8916570B2 (en) 2008-03-31 2014-12-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor agonists and antagonists
US9181253B2 (en) 2008-08-01 2015-11-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adenosine receptor agonists, partial agonists, and antagonists
AU2009276411B2 (en) 2008-08-01 2014-08-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor antagonists and partial agonists
US10441541B2 (en) * 2015-09-14 2019-10-15 New York University Methods and compositions for treating osteoarthritis and promoting cartilage formation
IL254535A0 (en) * 2017-09-17 2017-11-30 Can Fite Biopharma Ltd Adenosine a3 receptor ligand for use in the management of cytokine release syndrome
IL272078A (en) 2020-01-16 2021-07-29 Can Fite Biopharma Ltd Cannabinoids for use in therapy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7331094A (en) * 1993-07-13 1995-02-13 United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The A3 adenosine receptor agonists
US5688774A (en) 1993-07-13 1997-11-18 The United States Of America As Represented By The Department Of Health And Human Services A3 adenosine receptor agonists
JP2004135657A (ja) * 2002-08-21 2004-05-13 Kyowa Hakko Kogyo Co Ltd ヒトａ３アデノシン受容体を発現するトランスジェニック非ヒト哺乳動物
AU2003282359A1 (en) * 2002-11-19 2004-06-15 Can-Fite Biopharma Ltd. A3ar agonists for the treatment of inflammatory arthritis
GB0305150D0 (en) * 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Use of therapeutic compounds
GB0305153D0 (en) * 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Identification of therapeutic compounds
WO2005000331A2 (en) * 2003-06-04 2005-01-06 Mucosal Therapeutics, Inc. Compositions for the treatment and prevention of degenerative joint disorders
US7807675B2 (en) * 2004-04-02 2010-10-05 Denki Kagaku Kogyo Kabushiki Kaisha Hyaluronic acid-methotrexate conjugate
BRPI0517639A (pt) * 2004-11-08 2008-10-14 Can Fite Biopharma Ltd método para o tratamento de ressorção óssea acelerada, composição farmacêutica, e, uso de um agonista de a3ar
JP4842964B2 (ja) * 2004-12-02 2011-12-21 キャン−ファイト・バイオファーマ・リミテッド 炎症用生体マーカー
US20080051365A1 (en) * 2004-12-02 2008-02-28 Can-Fite Biopharma Ltd. Treatment of Inflammation

Also Published As

Publication number Publication date
AU2006321165B2 (en) 2010-04-22
CN101330909A (zh) 2008-12-24
EP1959939B1 (de) 2012-01-11
ES2379591T3 (es) 2012-04-27
US10265337B2 (en) 2019-04-23
JP2013166789A (ja) 2013-08-29
DK1959939T3 (da) 2012-04-23
KR101101252B1 (ko) 2012-01-04
JP2009517458A (ja) 2009-04-30
CN101330909B (zh) 2012-09-26
WO2007063538A1 (en) 2007-06-07
CA2622879A1 (en) 2007-06-07
US20080300213A1 (en) 2008-12-04
CA2622879C (en) 2011-07-05
EP1959939A1 (de) 2008-08-27
JP5339916B2 (ja) 2013-11-13
BRPI0619395A2 (pt) 2011-10-04
KR20080071609A (ko) 2008-08-04
AU2006321165A1 (en) 2007-06-07
US20160263142A1 (en) 2016-09-15

Similar Documents

Publication Publication Date Title
ATE540673T1 (de) Verwendung von a3-adenosin-rezeptor-agonisten bei der behandlung von osteoarthritis
BRPI0912411A8 (pt) uso de uma muteína de interleucina humana-2 (muteína de hil-2) ou de um fragmento da mesma, composição farmacêutica para o tratamento e/ou profilaxia de uma doença autoimune, uso de muteína de interleucina humana-2 (muteína de hil-2) ou de uma seção da mesma, agete para formação de células t regulatórias (treg) em um organismo, método para tratamento e/ou profilaxia de uma doença autoimune em um organismo, método para formação de células t regulatórias (treg) em um organismo, método para formação de células t regulatórias (treg) in vitro.
DE602006012725D1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
EA201100079A1 (ru) Производные триазоло[4,5-d]пирамидина и их применение в качестве антагонистов пуринового рецептора
LTPA2017009I1 (lt) Brutono tirozinkinazės inhibitoriai
EA200800555A1 (ru) Производные ксантина в качестве селективных агонистов hm74a
BRPI0618918B8 (pt) uso de um primeiro composto e um segundo composto para tratar uma condição de glicose sanguínea
CY1112889T1 (el) Αναλογα αζετιδινης αναστολεων νουκλεοσιδασης και φωσφορυλασης
MY147393A (en) Administration of dipeptidyl peptidase inhibitors
DE602006015509D1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
EA201100691A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты
EA200901133A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
BRPI0618552B8 (pt) compostos derivados de pirimidina ligados ao oxigênio,composição farmacêutica que inclui os ditos compostos,método de síntese dos compostos e usos terapêuticos dos mesmos
DE602006004844D1 (de) Pyrrolopyrimidine verwendbar als protein kinase inhibitoren
EA200901138A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
BRPI0817503B8 (pt) derivados de purina substituídos por pirimidina, composição farmacêutica compreendendo ditos compostos e uso dos mesmos para a prevenção ou tratamento de uma condição proliferativa
CY1113159T1 (el) Ανταγωνιστες υποδοχεα γλυκαγονης, παρασκευη και θεραπευτικες χρησεις
CY1109624T1 (el) Υποκατεστημενα παραγωγα θειοφαινιου ως ανταγωνιστες υποδοχεα γλυκογονου, παρασκευη και θεραπευτικες χρησεις
EA200970273A1 (ru) Применение 2-6-(3-аминопиперидин-1-ил)-3-метил-2,4-диоксо-3,4-дигидро-2н-пиримидин-1-илметил-4-фторбензонитрила
EA202191801A1 (ru) Гетероциклические ингибиторы mat2a и способы применения для лечения рака
DE602006017728D1 (de) Krebsbehandlung mittels fts und 2-deoxyglucose
WO2008023362A3 (en) Use of a combination of methotrexate and an a3ar agonist for the treatment of cancer
WO2007045705A3 (es) Compuestos para el tratamiento de la fibrilación auricular
BR0308515A (pt) Combinação de um antagonista de receptor de aldosterona com ácido nicotìnico ou um derivado de ácido nicotìnico
DE60014429D1 (de) Zusammensetzungen von adenosin a1 agonisten und 5ht3 agonisten